Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey

DR Lim, AS Dean, MR Taguinod-Santiago, A Borbe-Reyes, AM Cabibbe, M Zignol, RP Basilio, AMC Garfin, MCG Ama

Research output: Contribution to journalArticle

Abstract

Antimicrobial resistance (AMR) represents a global threat to public health and security. Misuse of antibiotics is the leading cause of AMR worldwide. Infections that are typically easily treatable can become life-threatening or even deadly. Multidrug-resistant (MDR) tuberculosis (TB) (defined as resistance to at least rifampicin and isoniazid, the two most powerful first-line anti-TB drugs) and extensively drug-resistant (XDR)-TB (defined as MDR-TB with additional resistance to any fluoroquinolone and a second-line injectable (SLI) agent) are forms of TB that are complex to treat, require longer and more toxic regimens [1], and have considerably worse prognosis and outcome [2, 3]. Resistance to anti-TB drugs poses a major challenge to ending the global TB epidemic by 2030 [4]. To estimate the burden of drug-resistant TB, and plan diagnostic and treatment services, surveillance of drug resistance among TB patients has been conducted worldwide since the 1990s [5].
Original languageEnglish
Article number1702571
JournalEuropean Respiratory Journal
Volume51
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey'. Together they form a unique fingerprint.

  • Cite this

    Lim, DR., Dean, AS., Taguinod-Santiago, MR., Borbe-Reyes, A., Cabibbe, AM., Zignol, M., Basilio, RP., Garfin, AMC., & Ama, MCG. (2018). Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey. European Respiratory Journal, 51(3), [1702571]. https://doi.org/10.1183/13993003.02571-2017